Annals of Research in Oncology’s Post

This study demonstrates the successful treatment (>93% complete response) of spontaneous tumors with Algorithmically Controlled Electroporation (ACE) utilizing a temperature-control algorithm with custom applicator to prevent treatment-associated thermal damage. ACE uses ultrashort electrical pulses to target and destroy cancer cells. This process uses active temperature control to prevent inadvertent thermal damage to nearby critical structures while maintaining optimal temperatures for therapeutic effectiveness. In this study, authors demonstrate the anti-tumor efficacy of ACE in a spontaneous veterinary model of equine melanoma. Complete response rates greater than 93% were achieved in all treatment groups demonstrating that ACE is a safe and effective treatment for solid tumors that can potentially be administered in an out-patient setting. The investigative team is currently working to bring this technology to the human clinic for the treatment of lung, liver, pancreatic, breast, prostate, and brain cancer.  For more information, read the article in #IEEE Transactions on Biomedical Engineering(#TBME): https://lnkd.in/gC5g8BDz #BiomedicalEngineering #IEEEEMBS #VeterinaryOncology #TumorTreatment #InnovativeTherapies #CancerResearch #MedicalTechnology #ClinicalAdvancement

Looking to boost your knowledge on von Hippel-Lindau disease (VHL) management? Join us for a live #webinar on June 26 @ 8AM EDT! #VHL is a complex condition requiring a collaborative approach from an interprofessional team. Join us to enhance your understanding and improve patient outcomes through collaboration and advanced treatment strategies. Register now to attend this interactive webinar and gain the latest insights on: ♦ Varying clinical manifestations of VHL-associated tumors across organ systems ♦ Genetic testing techniques for VHL, including benefits and limitations ♦ Emerging therapies for VHL-associated tumors, including the FDA approval of belzutifan ♦ Strategies for conveying genetic information to patients and family members ♦ Multisystemic management of VHL across the interprofessional team ♦ And much more! Don't miss out on this opportunity to expand your knowledge and expertise in VHL management. Click the link to register today! https://bit.ly/3x3qwlH #healthcare #medicaleducation #HealthcareWebinar #cme #NCPD #CE #healthcareprofessionals #medicalgenetics #geneticcounseling #genetics #GeneticCounselor #GeneticResearch #geneticsresearch #oncology #oncologists #nursepractitioner #physician #physicianassistant #nurse #oncologynurse

Do you want to hear more about this technology and #NIPT? Do you specialise in #gynaecology #obstetrics #oncology? Contact: genetics@ctie.eurofinseu.com More info: www.clinicalgenetics.ie #illumnia #healthcareinnovation #precisionmedicine #biotech #lifesciences #genomics #scientists #medicallaboratory #precisionmedicine

Hyperthermia: Heating Up the Fight Against Tumors🔥 Did you know that some of the advancements in using hyperthermia for treating human cancers trace back to groundbreaking work in veterinary medicine, specifically in treating sarcomas in dogs? In 2000, Dr. D.E. Thrall and his team published research showing that local hyperthermia—targeting tumors with temperatures between 41-43°C—could significantly improve tumor destruction. This research provided crucial insights into how heat can impact cancer cells, leading to better outcomes. 🌡️🔥 Why focus on sarcomas? These rapidly growing tumors, much like those in humans, outgrow their blood supply, making them particularly vulnerable to heat. Localized hyperthermia helps tumors absorb heat, which enhances the effectiveness of standard treatments like chemotherapy and radiation. The real benefit? This method not only aids in destroying the tumor but also protects surrounding healthy tissue, leading to improved prognosis and patient outcomes. A big thank you to the University of Tennessee for advancing this research and helping us better understand how to harness heat to target cancer cells effectively. 👉 Interested in learning more about hyperthermia and its potential in cancer care? At Williams Cancer Institute, we're applying these techniques to offer patients cutting-edge treatments. Schedule your free consultation today. Supporting Evidence: Thrall DE, Rosner GL, Azuma C, Larue SM, Case BC, Samulski T, Dewhirst MW. Using units of CEM 43 degrees C T90, local hyperthermia thermal dose can be delivered as prescribed. Int J Hyperthermia. 2000 Sep-Oct;16(5):415-28. doi: 10.1080/026567300416712. #Hyperthermia #CancerTreatment #LocalHyperthermia #SarcomaResearch #InnovativeOncology #WilliamsCancerInstitute #CancerBreakthrough #CancerCare #HeatVsCancer #VeterinaryResearch #PatientOutcomes

🩺📊 Seeking Improved Prophylaxis for Trans-Rectal Biopsies? Exciting Study Findings! Our groundbreaking study, utilizing Next-Generation Sequencing (NGS), has unveiled remarkable insights into the microbial landscape associated with trans-rectal biopsies. We are thrilled to share the compelling results and their implications for patient care. 📈 Results: Among the 68 patients analyzed, we observed the presence of multiple bacterial species, ranging from 2 to 16, with a median of 10. Notably, Bacteroides spp. (dorei, fragilis, caccae, massiliensis, uniformis, and vulgatus) emerged as the predominant flora in 26 men, followed by Escherichia coli in 18 patients and Prevotella (copri, timonensis, and corporis) in 11 individuals. Additionally, we detected multiple drug resistance genes in 69% of men, with 47% exhibiting resistance to fluoroquinolones, 7% to β-lactams (excluding fluoroquinolone resistance), and 31% demonstrating resistance to both groups. These findings empowered us to modify our empiric prophylaxis regimen, targeting the most dominant and aggressive pathogens identified in 37 patients. 💡 Insights: Incorporating a tailored NGS-guided prophylaxis approach, we successfully supplemented the prophylactic regimen with antifungal agents upon detecting fungal species in 27 men, 15 of whom harbored multiple fungal species. Excitingly, our novel prophylaxis strategy resulted in the avoidance of serious infectious complications, including urosepsis, in all patients within 30 days post-biopsy. The occurrence of epididymitis was limited to two cases, and cystitis was observed in only one patient. 🔎 Conclusions: The implementation of NGS technology allowed us to achieve truly individualized and targeted prophylaxis for patients undergoing trans-rectal biopsies. As we look ahead, further studies are warranted to compare the efficacy of NGS against standard culture and sensitivity methods for rectal swabs. Join the movement towards more effective and personalized prophylactic strategies! Stay tuned for upcoming research developments in this cutting-edge field. Together, let's elevate patient outcomes and redefine the standard of care for trans-rectal biopsies. www.microgendx.com #MedicalResearch #ProphylaxisInnovation #NGSTechnology #PrecisionMedicine #PatientCare #HealthcareAdvancements

I am thrilled to announce that our posters have been accepted for presentation at American College of Gastroenterology (ACG) 2024! We will share our latest research findings and contribute to the ongoing conversations in gastroenterology. I want to thank Faryal Altaf and Eeshal Fatima for their invaluable contributions to these projects. For anyone attending ACG 2024, I invite you to join us at our presentations and engage in discussions on the following topics: -Efficacy and Safety of Polyethylene Glycol Alone vs Combined Polyethylene Glycol and Linaclotide as Colonoscopy Preparation Regimens: A Systematic Review and Meta-Analysis** -Efficacy and Safety of Sintilimab in Patients With Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis** -Trends, Gender, and Racial Disparities in Mortality Related to Liver Diseases Associated With Substance Use Disorder in the United States: A Retrospective Analysis from 1999 to 2020** -Polyethylene Glycol Versus Oral Sulfate Solution for Colonoscopy: An Updated Systematic Review and Meta-Analysis** -Negative Immunochemical Fecal Occult Blood Test does not Detect Smaller Polyps – Colonoscopy Remains the Best Test for Colon Cancer Prevention** I am looking forward to seeing you there and exchanging insights. Let’s make ACG 2024 an enlightening and productive experience for all! #ACG2024 #Gastroenterology #Research #HealthcareInnovation

📣 🔔 Thrilled to share that I've been selected as a grant recipient by the European League Against Rheumatism (EULAR) to participate in the prestigious EULAR 2024 Congress in Vienna, Austria, from June 12th to 15th! 📅 🎖 At the congress, I'm honored to present my research on two fronts. Firstly, my work titled "The use of high-throughput technologies for molecular profiling in Rheumatoid Arthritis enables the identification of patient subgroups with distinctive disease activity and therapeutic response" has been chosen for a Poster Tour presentation, offering a unique opportunity to engage with peers in a dynamic format. Additionally, I'll be showcasing an academic poster titled "Uncovering novel common and distinctive gene signatures in rheumatoid arthritis and systemic lupus erythematosus through integrative transcriptomic analysis." 👨🔬 👨💻 This congress serves as an invaluable platform to exchange insights and collaborate with leading experts in rheumatology. I extend my heartfelt gratitude to EULAR for this remarkable opportunity and am eager to contribute to the advancement of research and patient care in this vital field. #EULAR2024 #Rheumatology #MedicalResearch #EULARCongress #GrantRecipient #ScienceAdvancement

Dr. Prasad Iyer MD MSc FASGE FACG AGAF, AGAF, continues to set new benchmarks in gastroenterology through his innovative work on esophageal diseases, including Barrett's esophagus and esophageal cancer. As Chair of the Division of Gastroenterology and Hepatology at Mayo Clinic Arizona, Dr. Iyer combines research, clinical practice, and education to drive meaningful advancements in the field. 2024 Highlights ✨ ⭐ Led a groundbreaking study using artificial intelligence to predict risks of Barrett’s esophagus and esophageal cancer, revolutionizing early detection. ⭐ Contributed to advancements in non-endoscopic screening and biomarker technologies. ⭐ Directed Mayo Clinic's Clinical Trialist Training Program, mentoring the next generation of clinical researchers. ⭐ Presented on esophageal disease innovations at the ACG 2024 Annual Meeting, delivering impactful insights on diagnosis and treatment. With over 200 peer-reviewed publications, Dr. Iyer’s dedication to innovation and clinical excellence makes him a leading voice in the global gastroenterology community. #Gastroenterology #EsophagealHealth #MedicalInnovation #BarrettsEsophagus #ClinicalResearch #MayoClinic #ACG2024 #AIinHealthcare #Endoscopy #HealthcareLeadership

#Review: Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications Drs. Christine Rasetti-Escargueil (The Institute of Cancer Research, London, UK) and Stefano Palea (Humana Biosciences, Labège, France) recently published an overview of the diversity of Botulinum Neurotoxins. The conventional therapeutic uses are presented as well as the engineering and formulation opportunities opening new avenues for therapeutic applications in many human pathologies. At Humana Biosciences, we are very proud of our contribution to this work. In our laboratories, we have validated in vitro and in vivo experimental models for testing natural and recombinant Botulinum Neurotoxins. For more details, read the paper published on MDPI_Toxins #botulinumtoxinA #botulinumtoxinB #botulinumneurotoxins    #NeurogenicDetrusorOveractivity  #OveractiveBladder #BladderPainSyndrome #TrigeminalNeuralgia #LowBackPainSciaticaPyalgia #Arthropathy #Cancer #Toxinotypes #NonNeuronalTargeting

Do you want to learn more about model-informed precision dosing #MIPD for #antiinfectives, #oncology, #inflammatory bowel diseases, and #transplant medicine? Check-out this article: 👇 https://lnkd.in/dbZVgmBu It was an extreme pleasure to write this piece together with Iris Minichmayr,Erwin Dreesen,Maddalena Centanni, Zhigang Wang,Yannick Hoffert, and Lena Friberg!